A program to develop recombinant vaccines for plague and botulinum neurotoxin serotypes A and B, and a program to develop a vaccine for Venezuelan equine encephalitis have received the FDA priority designation.
Fast track status allows the FDA to expedite review of drugs and biologics that demonstrate the potential to address unmet medical needs and are intended to treat serious or life-threatening conditions.
“At DVC, our mission is to expedite the development of biodefense products to protect the nation’s operating forces and citizens,” said DVC chief scientific officer, Dr Robert House. “We do this by applying for fast track status, which enables us to work closely with the FDA to more efficiently meet military biodefense needs.”